5,417 Shares in Axsome Therapeutics, Inc. $AXSM Acquired by Landscape Capital Management L.L.C.

Key Points

• Landscape Capital Management acquired 5,417 shares of Axsome Therapeutics, Inc. valued at approximately $632,000 in the first quarter, marking a significant investment in the company.
• Axsome Therapeutics has received strong analyst support, with a consensus rating of "Buy" and an average price target of $178.00 from multiple research firms.
• Despite recent insider selling, which saw over 102,000 shares traded, institutional investors still hold a substantial 81.49% of the company's stock.

Landscape Capital Management L.L.C. purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,417 shares of the company's stock, valued at approximately $632,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Principal Financial Group Inc. raised its stake in shares of Axsome Therapeutics by 42.8% in the 1st quarter. Principal Financial Group Inc. now owns 295,671 shares of the company's stock valued at $34,484,000 after buying an additional 88,606 shares in the last quarter. Penserra Capital Management LLC acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at $2,229,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Axsome Therapeutics by 20.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company's stock valued at $4,877,000 after buying an additional 9,928 shares in the last quarter. Trek Financial LLC acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at $3,446,000. Finally, Edgestream Partners L.P. acquired a new position in shares of Axsome Therapeutics in the 1st quarter valued at $8,174,000. 81.49% of the stock is owned by institutional investors.

Analyst Ratings Changes

AXSM has been the subject of a number of recent research reports. Morgan Stanley initiated coverage on shares of Axsome Therapeutics in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $190.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday, June 10th. Wells Fargo & Company raised shares of Axsome Therapeutics to a "strong-buy" rating in a report on Wednesday. Needham & Company LLC reiterated a "buy" rating and issued a $150.00 target price on shares of Axsome Therapeutics in a research note on Monday, August 4th. Finally, Cantor Fitzgerald upgraded shares of Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Two research analysts have rated the stock with a Strong Buy rating and thirteen have given a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $177.86.

Insider Buying and Selling at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 25,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $110.44, for a total value of $2,761,000.00. Following the transaction, the chief operating officer directly owned 5,783 shares in the company, valued at approximately $638,674.52. This represents a 81.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Hunter R. Murdock sold 7,500 shares of the company's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total transaction of $751,950.00. The disclosure for this sale can be found here. Insiders have sold a total of 116,172 shares of company stock worth $13,386,040 over the last ninety days. Insiders own 22.40% of the company's stock.

Axsome Therapeutics Trading Up 1.7%

Shares of NASDAQ:AXSM traded up $2.06 during trading on Thursday, hitting $124.06. 268,783 shares of the company's stock were exchanged, compared to its average volume of 761,602. The firm has a 50-day moving average price of $109.35 and a two-hundred day moving average price of $111.09. Axsome Therapeutics, Inc. has a 1-year low of $75.56 and a 1-year high of $139.13. The firm has a market cap of $6.19 billion, a P/E ratio of -24.47 and a beta of 0.54. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.92) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.08. The business had revenue of $150.04 million for the quarter, compared to analyst estimates of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. Equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.